| Bioactivity | Olamkicept (FE 999301) is a selective inhibitor of the soluble interleukin 6 (sIL-6R)/IL-6 complex. Olamkicept is a soluble gp130-Fc-fusion-protein and anti-inflammatory agent[1][2]. |
| Target | sIL-6R/IL-6 Complex |
| Invitro | Olamkicept (10 µg/mL，60 分钟) 抑制 HREC 中 IL-6 转信号介导的 STAT3 激活[5]。Olamkicept (10 µg/mL，60 分钟) 抑制 IL-6 转导信号诱导的 HREC 中 H2O2 水平的增加[5].Olamkicept (10 µg/mL，60 分钟) 抑制 IL-6 转导诱导的 HREC 细胞凋亡[5]。Olamkicept (0-1 µg/mL) 抑制 IL-11/重组 sIL-11R 诱导的 Ba/F3-gp130 细胞增殖[6]。 Western Blot Analysis[5] Cell Line: |
| In Vivo | Olamkicept (sgp130Fc) (0.01-10 mg/kg，皮下注射) 提高盲肠结扎穿孔 (CLP) 败血症小鼠模型的存活率[3]。Olamkicept (0.5 mg/kg，腹腔注射) 抑制盲肠结扎穿孔 (CLP) 诱导的败血症小鼠的炎症并提高存活率[4]。 Animal Model: |
| Name | Olamkicept |
| CAS | 1702282-14-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schreiber S, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology. 2021 Jun;160(7):2354-2366.e11. [2]. Zhang S, et al. Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2023 Mar 7;329(9):725-734. [3]. Barkhausen T, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011 Jun;39(6):1407-13. [4]. SHI Dan-dan, et al. IL-6 trans-signaling inhibitor sgp130Fc suppresses inflammation and regulates immune cells in mice with sepsis. Basic & Clinical Medicine. 2022, 42 (12): 1895-1899. [5]. Valle ML, et al. Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells. Exp Eye Res. 2019 Jan;178:27-36. [6]. Lokau J, et al. Proteolytic Cleavage Governs Interleukin-11 Trans-signaling. Cell Rep. 2016 Feb 23;14(7):1761-1773. |